BridgeBio Pharma Research and Development Expenses 2018-2025 | BBIO
BridgeBio Pharma annual/quarterly research and development expenses history and growth rate from 2018 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
- BridgeBio Pharma research and development expenses for the quarter ending March 31, 2025 were $0.111B, a 20.96% decline year-over-year.
- BridgeBio Pharma research and development expenses for the twelve months ending March 31, 2025 were $0.477B, a 5.34% decline year-over-year.
- BridgeBio Pharma annual research and development expenses for 2024 were $0.506B, a 11.14% increase from 2023.
- BridgeBio Pharma annual research and development expenses for 2023 were $0.456B, a 14.08% increase from 2022.
- BridgeBio Pharma annual research and development expenses for 2022 were $0.399B, a 11.43% decline from 2021.
BridgeBio Pharma Annual Research and Development Expenses
(Millions of US $) |
| 2024 |
$506 |
| 2023 |
$456 |
| 2022 |
$399 |
| 2021 |
$451 |
| 2020 |
$337 |
| 2019 |
$210 |
| 2018 |
$140 |
| 2017 |
$31 |
BridgeBio Pharma Quarterly Research and Development Expenses
(Millions of US $) |
| 2025-03-31 |
$111 |
| 2024-12-31 |
$130 |
| 2024-09-30 |
$120 |
| 2024-06-30 |
$115 |
| 2024-03-31 |
$141 |
| 2023-12-31 |
$130 |
| 2023-09-30 |
$125 |
| 2023-06-30 |
$107 |
| 2023-03-31 |
$93 |
| 2022-12-31 |
$91 |
| 2022-09-30 |
$93 |
| 2022-06-30 |
$108 |
| 2022-03-31 |
$108 |
| 2021-12-31 |
$122 |
| 2021-09-30 |
$104 |
| 2021-06-30 |
$102 |
| 2021-03-31 |
$123 |
| 2020-12-31 |
$90 |
| 2020-09-30 |
$92 |
| 2020-06-30 |
$87 |
| 2020-03-31 |
$68 |
| 2019-12-31 |
$57 |
| 2019-09-30 |
$55 |
| 2019-06-30 |
$52 |
| 2019-03-31 |
$45 |
| 2018-12-31 |
|
| 2018-09-30 |
$31 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.397B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
